A new pathway to treat PAH targeted by the first activin signaling inhibitor (ASI)

31 August 2025 (15:23 - 15:31)

Organised by:

About the speaker

Doctor Maria Pilar Escribano Subias

12th of October University Hospital, Madrid (Spain)

5 More presentations in this session

Presentation thumbnail

Welcome

Presentation thumbnail

Right ventricular (RV) function assessment in PAH: why do we care?

Professor V. Moles (Ann Arbor, US)

Presentation thumbnail

Clinical data into context: effect of sotatercept on right ventricular (RV) function and structure

Doctor A. Vaidya (Temple, US)

Presentation thumbnail

Considerations on clinical implications

Professor S. Rosenkranz (Cologne, DE)

Presentation thumbnail

Q&A

Professor S. Rosenkranz (Cologne, DE)

Access the full session

Session thumbnail

A new way to treat pulmonary arterial hypertension (PAH) that improves hemodynamics and right ventricular function

The Event

Event poster

ESC Congress 2025

31 August 2025 15:23 CET

You may be interested in

Congress Presentation

Inhibin Beta-A is a novel gene involved in the development of pulmonary arterial hypertension through inhibiting BMPRII-signaling in endothelial cells

3 September 2019

Congress Session

Innovative drug therapies in heart failure

18 May 2025

Congress Presentation

UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)

28 August 2022

Congress Presentation

Development of KER-012, a modified ActRIIB ligand trap, for the treatment of pulmonary arterial hypertension

27 August 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources